These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29795759)

  • 1. Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes.
    Neelamkavil SF; Stamford AW; Kowalski T; Biswas D; Boyle C; Chackalamannil S; Xia Y; Jayne C; Neustadt B; Hao J; Liu H; Dai X; Baker H; Hawes B; O'Neill K; Tang H; Greenlee WJ
    ACS Med Chem Lett; 2018 May; 9(5):457-461. PubMed ID: 29795759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes.
    Pola S; Shah SR; Pingali H; Zaware P; Thube B; Makadia P; Patel H; Bandyopadhyay D; Rath A; Giri S; Patel JH; Ranvir RK; Sundar SR; Patel H; Kumar J; Jain MR
    Bioorg Med Chem; 2021 Apr; 35():116071. PubMed ID: 33611013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of the oxazabicyclo[3.3.1]nonane derivatives as potent and orally active GPR119 agonists.
    Dai X; Stamford A; Liu H; Neustadt B; Hao J; Kowalski T; Hawes B; Xu X; Baker H; O'Neill K; Woods M; Tang H; Greenlee W
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5291-4. PubMed ID: 26433449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives.
    Kubo O; Takami K; Kamaura M; Watanabe K; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Kitazaki T; Murata T; Sato K
    Bioorg Med Chem; 2021 Jul; 41():116208. PubMed ID: 34010766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
    Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
    Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
    Shah U; Kowalski TJ
    Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
    Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
    Shah U
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists.
    Sato K; Sugimoto H; Rikimaru K; Imoto H; Kamaura M; Negoro N; Tsujihata Y; Miyashita H; Odani T; Murata T
    Bioorg Med Chem; 2014 Mar; 22(5):1649-66. PubMed ID: 24508142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
    Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
    Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model.
    Park YH; Choi HH; Lee DH; Chung SY; Yang NY; Kim DH; Ju MK; Han TD; Nam SY; Kim KW
    Arch Pharm Res; 2017 Jun; 40(6):772-782. PubMed ID: 28593550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
    Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
    Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion.
    Yoshida S; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
    Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
    Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
    Zhou Y; Wang Y; Zhang L; Tang C; Feng B
    Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.